

Wen-yue Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7877158/publications.pdf>

Version: 2024-02-01

41
papers

1,444
citations

489802

18
h-index

388640

36
g-index

43
all docs

43
docs citations

43
times ranked

3091
citing authors

#	ARTICLE	IF	CITATIONS
1	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 183-195.	4.5	6
2	Free Triiodothyronine and Free Triiodothyronine to Free Thyroxine Ratio Predict All-Cause Mortality in Patients with Diabetic Foot Ulcers. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 467-476.	1.1	9
3	Three Nutritional Indices Are Effective Predictors of Mortality in Patients With Type 2 Diabetes and Foot Ulcers. <i>Frontiers in Nutrition</i> , 2022, 9, 851274.	1.6	8
4	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 864570.	1.2	5
5	<i>FNDC5</i> polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2021, 126, 813-824.	1.2	11
6	Extrapulmonary complications of COVID-19: A multisystem disease?. <i>Journal of Medical Virology</i> , 2021, 93, 323-335.	2.5	131
7	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
8	Association between heart rate-corrected QT interval and severe peripheral arterial disease in patients with type 2 diabetes and foot ulcers. <i>Endocrine Connections</i> , 2021, 10, 845-851.	0.8	9
9	Effect of <i>PNPLA3</i> polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1057-1064.	1.4	27
10	Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 80-86.	0.8	7
11	Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west?. <i>BMC Gastroenterology</i> , 2020, 20, 139.	0.8	23
12	Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1804-1812.	1.4	15
13	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001174.	1.2	21
14	Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154244.	1.5	281
15	Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154249.	1.5	25
16	A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients. <i>Journal of General Internal Medicine</i> , 2020, 35, 2205-2206.	1.3	47
17	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-7.	0.7	329
18	Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. <i>United European Gastroenterology Journal</i> , 2019, 7, 1124-1134.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Metabolic Acidosis in Critically Ill Cirrhotic Patients with Acute Kidney Injury. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-10.	0.7	5
20	A Novel Use of Model for End-Stage Liver Disease (MELD) Score in Guiding Therapeutic Antibiotics Choice for Critically Ill Cirrhotic Patients. <i>Medical Science Monitor</i> , 2019, 25, 5005-5014.	0.5	0
21	MetS Risk Score: A Clear Scoring Model to Predict a 3-Year Risk for Metabolic Syndrome. <i>Hormone and Metabolic Research</i> , 2018, 50, 683-689.	0.7	14
22	Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-8.	1.4	9
23	The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , 2017, 468, 17-24.	0.5	8
24	Scoring model to predict outcome in critically ill cirrhotic patients with acute respiratory failure: comparison with MELD scoring models and CLIF-SOFA score. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 857-864.	1.4	3
25	Xenogeneic Decellularized Scaffold: A Novel Platform for Ovary Regeneration. <i>Tissue Engineering - Part C: Methods</i> , 2017, 23, 61-71.	1.1	49
26	NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , 2017, 475, 44-50.	0.5	12
27	Elevation of plateletcrit increasing the risk of non-alcoholic fatty liver disease development in female adults: A large population-based study. <i>Clinica Chimica Acta</i> , 2017, 474, 28-33.	0.5	5
28	AKI-CLIF-SOFA: a novel prognostic score for critically ill cirrhotic patients with acute kidney injury. <i>Aging</i> , 2017, 9, 286-296.	1.4	11
29	Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients. <i>PLoS ONE</i> , 2016, 11, e0166085.	1.1	11
30	Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. <i>BMJ Open</i> , 2016, 6, e013781.	0.8	48
31	Targeting endoplasmic reticulum stress in liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1041-1052.	1.4	34
32	Kidney bioengineering in regenerative medicine: An emerging therapy for kidney disease. <i>Cytotherapy</i> , 2016, 18, 186-197.	0.3	17
33	Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 375-387.	1.5	22
34	Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. <i>Oncotarget</i> , 2016, 7, 5728-5737.	0.8	37
35	Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in chinese adults: a large population-based study. <i>Oncotarget</i> , 2016, 7, 14241-14250.	0.8	6
36	Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. <i>Oncotarget</i> , 2016, 7, 25516-25527.	0.8	52

#	ARTICLE	IF	CITATIONS
37	Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. PLoS ONE, 2015, 10, e0129000.	1.1	15
38	Recent advances in re-engineered liver: de-cellularization and re-cellularization techniques. Cytotherapy, 2015, 17, 1015-1024.	0.3	5
39	Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. Expert Opinion on Therapeutic Targets, 2015, 19, 675-685.	1.5	28
40	Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget, 2015, 6, 19880-19890.	0.8	43
41	The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opinion on Therapeutic Targets, 2014, 18, 1305-1313.	1.5	22